help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Swenson, E. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Swenson, E. R.
American Journal of Respiratory and Critical Care Medicine Vol 169. pp. 8-9, (2004)
© 2004 American Thoracic Society


Editorial

Therapeutic Hypercapnic Acidosis

Pushing the Envelope

Erik R. Swenson, M.D.

University of Washington Seattle, Washington

Should our experience and acceptance of permissive hypercapnia with lung-protective ventilation lead us to intentionally impose hypercapnia (therapeutic hypercapnia) in patients with acute lung injury? In this issue of the Journal (pp. 46–56), Laffey and colleagues point us in that direction (1). They added 5% CO2 to the inspired gas of rabbits with endotoxin-mediated lung injury to generate PaCO2 values of 70–75 mm Hg and pH values as low as 7.10. Not only was this well tolerated, but a myriad of physiological, biochemical, and histological measures of lung damage and inflammation were considerably attenuated, and mortality was reduced. Although others have shown that inspired carbon dioxide (12–25%) given prophylactically reduces ischemia–reperfusion (2, 3) and ventilator-induced lung injury (4, 5), this study (1) is the first to show a benefit when hypercapnia is administered after injury is established.

Until recently, it was standard practice to correct hypercapnic acidosis with high volumes and pressures, if necessary, owing to perceived dangers of respiratory acidosis itself, especially hemodynamic depression. Evidence for harm has always been weak, as Laffey and coworkers (1) nicely illustrate. Their control and sick hypercapnic rabbits had higher blood pressures, lesser lactic acidosis, and better oxygenation than did the normocapnic controls. This remarkable tolerance to acute hypercapnia was initially noted in the 1950s when the first blood gas electrodes revealed surprisingly profound hypercapnia (PaCO2 above 150 mm Hg, pH less than 7.00) in successful thoracic surgical cases (6). A PaCO2 of 375 mm Hg secondary to prolonged inadvertent hypoventilation with complete recovery has been reported (6). Permissive hypercapnia—purposefully limiting tidal volumes and accepting hypercapnia—did not gain credence until studies in status asthmaticus were undertaken in the 1980s (7). Death rates of 20% in historial controls were reduced to almost zero largely by preventing pneumothoraces and hemodynamic depression, even with PaCO2 values above 100 mm Hg. Acute hypercapnic acidosis is well tolerated as long as perfusion and arterial oxygenation are maintained. This is due to active intracellular pH defense mechanisms that pump hydrogen ion out into the extracellular space and a neuroendocrine sympathetic response that maintains cardiac output and blood pressure despite direct negative inotropic and vasodilating effects of hypercapnia (6, 8).

Although acute hypercapnia is tolerable and permits use of low tidal volumes and pressures, the concept that hypercapnia might have direct therapeutic effects in injury states, as reported by Laffey and coworkers (1), arose from studies in the 1970s and 1980s revealing a ‘pH paradox’. In tissue culture and isolated organ studies, including the lung (reviewed in [8, 9]), recovery after anoxia and/or ischemia was always greater if resuscitation occurred in an acidic milieu (pH < 7.00) and, conversely, was worse with alkalotic resuscitation. These studies established that metabolic and respiratory acidoses blunt many oxidative and inflammatory cascades initiated when tissues are reoxygenated. Because proteins generally have pH optima near physiologic pH, it is not surprising that acidosis reduces oxygen and nitrogen radical species generation, diminishes proinflammatory cytokine production, impairs neutrophil chemotaxis, and inhibits many proteases, nucleases, and phospholipases activated in injured cells (8, 9). Acting on these data, Shibata and coworkers (2) imposed prophylactic hypercapnia with 12–25% inspired CO2 begun before the onset of damage in ex vivo perfused rabbit lungs undergoing ischemia–reperfusion injury or oxidant-induced injury. They showed that features of microvascular permeability were mitigated with acidosis. Other investigators in ex vivo and in vivo studies subsequently demonstrated favorable compliance, gas exchange, cytokine generation, oxygen radical formation, and histological results (reviewed in [9, 10]). Laffey and colleagues (1) applied this strategy at a lower dose (with a lung-protective tidal volume of 4.5 ml/kg) in a clinically relevant model of bacterial-related lung injury (intratracheal endotoxin administration). They found that 5% inspired CO2, started either before (prophylactic) or 30 minutes after intratracheal endotoxin administration (therapeutic), was equally effective. They report considerably better physiological parameters (improved gas exchange, compliance, and airways resistance), more normal histology (decreased inflammatory cell infiltration and alveolar/tissue edema), and favorable biochemical results (reduced tissue and epithelial lining fluid nitric oxide metabolite concentrations, and only a slight increase in nitrotyrosine formation) with inspired CO2 even after the onset of injury. The favorable nitric oxide data are welcome because others using more intense acidotic regimens (hydrochloric acid infusions or 15% CO2) have warned of increased nitric oxide production and tissue injury (11). Lastly, the impressive results of Laffey and coworkers (1) were associated with a significant reduction in mortality (33 versus 11%). The fact that 5% inspired CO2 is efficacious when started in the midst of inflammation is an encouraging, clinically relevant finding because most often we are able to intervene only after the onset of lung damage.

Yet, therapeutic hypercapnia, whether by hypoventilation or low concentrations of inspired CO2 (as administered by Laffey and coworkers [1] in healthy animals), may not be an easy strategy to initiate or sustain in critically ill patients, many of whom have underlying chronic illnesses and acute organ dysfunction that may limit their tolerance and ability to compensate against hypercapnia. Paramount is the fact that only sterile, noninfectious injuries have been studied, and only over several hours in otherwise healthy animals. Given that hypercapnic acidosis results in a broad-based partial suppression of many events critical to microbial killing, will it be beneficial in septic states? Might it not increase the likelihood of secondary hospital-acquired infections? It is mandatory to investigate this question with live bacterial challenges, both blood and airway borne. Animal models that simulate patients with compromised cardiac, renal, and cerebral function should be studied to determine whether such individuals can mount and tolerate the resulting strong neurosympathetic tone and known cardiovascular responses evoked by hypercapnic acidosis, which may cause myocardial oxygen supply–demand insufficiency, renal vasoconstriction, antidiuresis, cerebral vasodilation, and pulmonary hypertension (9, 10)?

Should hypercapnia prove therapeutic, should we administer it by hypoventilation or by addition of inspired CO2 as did Laffey and coworkers (1)? Inspired CO2 might be the better choice. First, Fiehl and coworkers (12) showed that permissive hypoventilation (6 versus 10 ml/kg) leads to a greater shunt fraction and impaired gas exchange. Second, because the lung is not homogenously injured, the few remaining, more compliant units may still be over-ventilated (high ventilation–perfusion ratio) and have lower regional PACO2 values (less than 20 mm Hg) and higher local, possibly alkalotic and injurious (13), tissue pH, despite a lower minute ventilation. If the intention is to keep lung uniformly acidotic to suppress local inflammatory processes, then inspired CO2 guarantees that all regions, at a minimum, will never have a PCO2 below the inspired value. These questions of both clinical efficacy and best implementation strategy will require well planned and careful prospective studies, but given the provocative preclinical data of Laffey and coworkers (1), the answers are worth pursuing.

FOOTNOTES

Conflict of Interest statement: E.R.S. has no declared conflict of interest.

REFERENCES

  1. Laffey JG, Honan D, Hopkins N, Hyvelin J-M, Boylan JF, McLoughlin P. Hypercapnic acidosis attenuates endotoxin-induced acute lung injury. Am J Respir Crit Care Med 2004;169:46–56.[Abstract/Free Full Text]
  2. Shibata K, Cregg N, Engelberts D, Takeuchi A, Fedorko L, Kavanagh BP. Hypercapnia acidosis may attenuate acute lung injury by inhibition of endogenous xanthine oxidase. Am J Respir Crit Care Med 1998;158:1578–1584.[Abstract/Free Full Text]
  3. Laffey JG, Tanaka M, Engelberts D, Luo X, Yuan S, Tanswell AK, Post M, Lindsay T, Kavanagh BP. Therapeutic hypercapnia reduces pulmonary and systemic injury following in vivo lung reperfusion. Am J Respir Crit Care Med 2000;162:399–405.[Abstract/Free Full Text]
  4. Brochard AF, Hotchkiss JR, Vannay C, Markert M, Sauty A, Fiehl F, Schaller M-D. Protective effects of hypercapnic acidosis on ventilator-induced lung injury. Am J Respir Crit Care Med 2001;164:802–806.[Abstract/Free Full Text]
  5. Sinclair SE, Kregenow DA, Lamm WJE, Starr IR, Chi E, Hlastala MP. Hypercapnic acidosis is protective in an in vivo model of ventilator-induced lung injury. Am J Respir Crit Care Med 2002;166:403–408.[Abstract/Free Full Text]
  6. Potkin R, Swenson ER. Resuscitation from severe acute hypercarbia: determinants of tolerance and survival. Chest 1992;102:1742–1745.[Abstract/Free Full Text]
  7. Darioli R, Perret C. Mechanical controlled hypoventilation in status asthmaticus. Am Rev Respir Dis 1984;129:385–387.[Medline]
  8. Swenson ER. Metabolic acidosis. Respir Care 2001;46:342–353.[Medline]
  9. Laffey JG, Kavanagh BP. Carbon dioxide and the critically ill: too little of a good thing? Lancet 1999;354:1283–1286.[CrossRef][Medline]
  10. Kregenow DA, Swenson ER. Hypercapnic acidosis: implications for permissive and therapeutic hypercapnia. Eur Respir J 2002;20:6–11.[Free Full Text]
  11. Lang JD, Chumley P, Eiserich JP, Estevez A, Bamberg T, Adhami A, Crow J, Freeman BA. Hypercapnia induces injury to alveolar cells via a nitric oxide–dependent pathway. Am J Physiol 2000;279:L994–L1004.
  12. Fiehl F, Eckert P, Brimioulle S, Jacobs O, Schaller M-D, Melot C, Naeije R. Permissive hypercapnia impairs pulmonary gas exchange in the acute respiratory distress syndrome. Am J Respir Crit Care Med 2000;162:209–215.[Abstract/Free Full Text]
  13. Laffey JG, Engelberts D, Kavanagh BP. Injurious effects of hypocapnic alkalosis in the isolated lung. Am J Respir Crit Care Med 2000;162:399–405.



This article has been cited by other articles:


Home page
ChestHome page
S. E. Sinclair, D. A. Kregenow, I. Starr, C. Schimmel, W. J.E. Lamm, M. P. Hlastala, and E. R. Swenson
Therapeutic Hypercapnia and Ventilation-Perfusion Matching in Acute Lung Injury: Low Minute Ventilation vs Inspired CO2.
Chest, July 1, 2006; 130(1): 85 - 92.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
B. P. Kavanagh
Therapeutic Hypercapnia: Careful Science, Better Trials
Am. J. Respir. Crit. Care Med., January 15, 2005; 171(2): 96 - 97.
[Full Text] [PDF]


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Swenson, E. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Swenson, E. R.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2004 American Thoracic Society